Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study
Why the study?
Does ticagrelor reduce mortality following pulmonary adverse events and sepsis compared to clopidogrel in patients with acute coronary syndromes?
Population
18,421 patients with acute coronary syndromes from the PLATO study
Comparison
Ticagrelor vs Clopidogrel
Design
Cohort
Authors
Discussion
Loading...
Member takes
Implication
May support ticagrelor preference in ACS to lower pulmonary risk; hypothesis-generating and leaves causal effects open.
Structured PICO
Does ticagrelor reduce mortality following pulmonary adverse events and sepsis compared to clopidogrel in patients with acute coronary syndromes?
P
Population
18,421 patients with acute coronary syndromes from the PLATO study
I
Intervention
Ticagrelor
C
Comparator
Clopidogrel
O
Outcome
Adverse events consistent with pulmonary infection or sepsis, and subsequent mortalityhard clinical
Ticagrelor is associated with a lower risk of mortality following pulmonary adverse events and sepsis compared to clopidogrel in patients with acute coronary syndromes, potentially due to differential effects on immune signaling.
Cite This Study
Storey et al. (2013) studied this question.